## 1 Title

- 2 Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID
- 3 lung disease

## 4 Authors

- 5 Puja Mehta<sup>2\*</sup>, Blanca Sanz-Magallón Duque de Estrada<sup>1\*</sup>†, Emma K Denneny<sup>2\*</sup>,
- 6 Kane Foster<sup>3</sup>, Carolin T Turner<sup>1</sup>, Andreas Mayer<sup>1</sup>, Martina Milighetti<sup>1</sup>, Manuela Platé<sup>2</sup>,
- 7 Kaylee B Worlock<sup>2</sup>, Masahiro Yoshida<sup>2</sup>, Jeremy S Brown<sup>2</sup>, Marko Z Nikolić<sup>2</sup>, Benjamin
- 8 M Chain<sup>1</sup>, Mahdad Noursadeghi<sup>1</sup>, Rachel C Chambers<sup>2\*</sup>, Joanna C Porter<sup>2\*</sup>, Gillian S
- 9 Tomlinson<sup>1\*</sup>†
- 10 \*These authors contributed equally.
- 11 †Corresponding authors.

## 12 Affiliations

- 13 1. Division of Infection and Immunity, University College London, London, UK
- 14 2. UCL Respiratory, University College London, London, UK
- 15 3. UCL Cancer Institute, University College London, London, UK

## 16 Corresponding authors

blanca.estrada.16@ucl.ac.uk

- 17 Dr Gillian S Tomlinson and Dr Blanca Sanz-Magallón Duque de Estrada, Infection and
- 18 Immunity, University College London, Cruciform Building, Gower Street, London
- 19 WC1E 6BT, United Kingdom. Email: g.tomlinson@ucl.ac.uk,
- 21

#### 22 Abstract

Background Persistent radiological lung abnormalities are evident in many survivors of acute coronavirus disease 2019 (COVID-19). Consolidation and ground glass opacities are interpreted to indicate subacute inflammation whereas reticulation is thought to reflect fibrosis. We sought to identify differences at molecular and cellular level, in the local immunopathology of post-COVID inflammation and fibrosis.

Methods We compared single-cell transcriptomic profiles and T cell receptor (TCR) repertoires of bronchoalveolar cells obtained from convalescent individuals with each radiological pattern, targeting lung segments affected by the predominant abnormality. Results Single-cell transcriptomes of inflammatory and fibrotic post-COVID lung disease closely resembled each other across all cell types. However, CD4 central memory T cells and CD8 effector memory T cells were significantly more abundant in those with inflammatory radiology. Clustering of similar TCRs from multiple donors

35 was a striking feature of both phenotypes, consistent with tissue localised antigen-36 specific immune responses. There was no enrichment for known SARS-CoV-2-37 reactive TCRs, raising the possibility of T cell-mediated immunopathology driven by 38 failure in immune self-tolerance.

39 Conclusions We found no evidence that post-COVID radiographic inflammation and 40 fibrosis are associated with differential immmunopathological pathways. Both show 41 evidence of shared antigen-specific T cell responses, suggesting a role for therapies 42 targeting T cells in limiting post-COVID lung damage.

#### 44 INTRODUCTION

Persistent functional and radiological lung abnormalities are evident at one year in 45 approximately 20% of people who survive acute coronavirus disease 2019 (COVID-46 19) (Fabbri et al., 2023). Current understanding of the immunopathogenic 47 48 mechanisms responsible for post-COVID lung disease (PCLD) is very limited (Mehta 49 et al., 2022). Elevated numbers of airway CD4 and CD8 T cells have been reported 50 (Cheon et al., 2021; Vijayakumar et al., 2022) and the post-COVID airway proteome 51 displays evidence of ongoing epithelial injury that resolves with time (Vijayakumar et 52 al., 2022). It is imperative to address this knowledge deficit to inform therapeutic 53 interventions that could expedite resolution of pathology and minimize irreversible tissue damage, to reduce long term morbidity secondary to PCLD and the attendant 54 55 burden on healthcare services.

56 There has been the impression of two major radiological patterns in PCLD: 57 consolidation and ground glass opacities, thought to represent subacute inflammation, 58 and reticulation, widely interpreted as fibrosis (Fabbri et al., 2023; Stewart et al., 2022). 59 Inflammation predominates during acute COVID-19, but fibrosis is evident on 32% of computed tomography (CT) scans during hospitalisation. Follow-up imaging within the 60 61 first year suggests radiological sequelae reduce with time, with less marked 62 improvement in fibrosis (Fabbri et al., 2023). We hypothesised that these distinct 63 radiological changes reflect distinct pathogenic mechanisms, which may require 64 different treatments. We sought to evaluate the molecular characteristics of cellular function at the site of disease in PCLD, by single-cell RNA sequencing (scRNAseq) of 65 66 bronchoalveolar cells from convalescent individuals infected during the first or second 67 waves of the pandemic, with predominant CT features of inflammation or fibrosis at

68 the time of sampling.

69 We showed that in comparison to fibrotic PCLD, the bronchoalveolar environment of 70 inflammatory PCLD was enriched for CD4 T central memory cells (TCM) and CD8 T 71 effector memory cells (TEM). Consistent with this finding, a higher proportion of CD4 72 TCM clones were expanded in the inflammatory phenotype. Both inflammatory and 73 fibrotic PCLD bronchoalveolar T cells exhibited high levels of T cell receptor (TCR) 74 clustering, indicative of an antigen-specific immune response, but there was no 75 enrichment for known severe acute respiratory syndrome coronavirus 2 (SARS-CoV-76 2)-reactive sequences. No major differences were evident in any of the cell type-77 specific transcriptomic profiles of the two radiological phenotypes, suggesting that they 78 may represent different manifestations of the same disease process.

#### 79 **Results**

#### 80 Increased abundance of bronchoalveolar T cells in inflammatory PCLD

Individuals undergoing bronchoscopy for clinical investigation of persistent respiratory 81 symptoms and predominant radiological features of either inflammation or fibrosis 82 83 following acute COVID-19, with no previous evidence of interstitial lung disease (ILD) 84 were recruited (Figure 1a). Bronchoalveolar lavage (BAL) samples from lung 85 segments affected by the predominant abnormality were obtained from five subjects with each radiological pattern (Figure 1a). Clinical and demographic characteristics 86 87 are provided in Table 1 and Supplementary Table 1. Evaluation of the composition of 88 post-COVID BAL by scRNAseq revealed that macrophages dominated in all subjects. 89 with smaller T cell, NK T cell, dendritic cell, epithelial and B cell populations also 90 identified (Figure 1b-d and Supplementary Figure 1a-d). Each of the cell types 91 expressed high levels of independently established marker genes (Adams et al., 2020;

92 Cheng et al., 2021; David et al., 2021; Davies et al., 2013; Davis and Wypych, 2021; 93 Gardell and Parker, 2017; Glass et al., 2020; Murray and Wynn, 2011; Tsyklauri et al., 94 2023; van Aalderen et al., 2021; Villani et al., 2017), validating our annotations (Figure 95 1d). The notable difference between the two phenotypes was significantly higher 96 abundance of CD4 T cells and CD8 T cells in inflammatory PCLD (Figure 1e). The 97 relative proportions of the other seven cell types present were not found to differ 98 between the two radiological phenotypes, providing confidence our analysis was not 99 confounded by compositional bias, where alterations in the proportion of one cell type 100 lead to many other cell types being falsely identified as differentially abundant.

101 To explore differences in cell type-specific transcriptional profiles between the two 102 radiological phenotypes, we first aggregated gene expression count data for each cell 103 type for each donor to form "pseudobulks". We leveraged the ability of pseudobulk 104 statistical approaches to account for variability of biological replicates, allowing 105 detection of genuine differential gene expression whilst minimizing false discoveries 106 (Squair et al., 2021). Very few cell type-specific differentially expressed genes were 107 identified (Supplementary Table 2), which precluded further bioinformatic analysis and 108 suggested the transcriptomes of inflammatory and fibrotic PCLD were similar for all 109 cell types.

Detection of transcriptomic differences between the two groups using pseudobulk statistical analysis may have been limited by small sample size. Therefore, we repeated the comparison of inflammatory and fibrotic PCLD at the level of individual cells. Single-cell statistical analysis identified thousands of cell type-specific differentially expressed genes in each radiological phenotype. However, single-cell differential gene expression analysis has a propensity for false positive results (Squair

et al., 2021). To mitigate against this, we sought to assess whether differentially
expressed gene lists represented differentially enriched biological pathways in the two
study groups. This was not evident at the level of biological processes or upstream
regulator analysis (Supplementary Figure 2 and 3), which suggested enrichment of
overlapping processes and pathways despite apparent differential gene expression.
Hence, our single-cell analysis also supports the outcome of the pseudobulk analysis.

## 122 CD4 central memory and CD8 effector memory are the predominant T cell 123 subsets in PCLD

124 Given that greater abundance of T cells in inflammatory cases was the only robust 125 difference between the two PCLD radiological phenotypes, we re-clustered these 126 populations alone to undertake a more detailed analysis. This revealed CD4 TCM and 127 CD8 TEM as the two predominant T cell subsets in the PCLD bronchoalveolar 128 environment, and a smaller population of regulatory T cells (Treg). A small mixed T 129 cell cluster, which expressed high levels of interferon-stimulated genes and an NK cell 130 cluster were also present in all samples. A minor population of gamma delta T cells 131 was identified in one individual with inflammatory PCLD (Figure 2a-c). There was no difference in the relative proportions of any T cell subset between the two PCLD 132 133 phenotypes (Figure 2d).

Analysis of T cell subset pseudobulks revealed no genes as differentially expressed in either group (Supplementary Table 2), consistent with our earlier observation of few differences between the transcriptional programmes of the two PCLD phenotypes at the level of broad cell types defined using the full dataset. In single-cell differential expression analysis of T cells, genes expressed at a significantly higher level in CD4 TCM and CD8 TEM in inflammatory PCLD exhibited weak enrichment for immune

140 response signalling pathways (Supplementary Figure 4a). Robust enrichment of 141 cellular pathways in anti-viral responses was evident for genes expressed at a 142 significantly higher level in CD4 TCM and CD8 TEM in fibrotic PCLD (Supplementary 143 Figure 4b), but this was not supported by enrichment for Type I interferon signalling in 144 upstream regulator analysis (Supplementary Figure 5b). Interestingly, interleukin (IL)2 145 and IL15 were the most statistically significant upstream regulators of CD4 TCM and 146 CD8 TEM differentially expressed genes in inflammatory PCLD but not fibrotic PCLD, 147 consistent with the notion of cytokine driven proliferation leading to increased 148 abundance of T cells in the former phenotype (Supplementary Figure 5a-c).

# Alveolar macrophage and monocyte subsets in PCLD are consistent with healthy airspace myeloid populations

151 Macrophages are the most abundant cell types in healthy airspaces (Mould et al., 152 2021) and were also found to be the most abundant cell type in PCLD BAL samples 153 in the present study. Macrophage subpopulations have been implicated in the 154 pathogenesis of fibrosis associated with severe COVID-19 and idiopathic pulmonary 155 fibrosis (Nouno et al., 2019; Wendisch et al., 2021). We therefore re-clustered 156 macrophages alone to further our understanding of macrophage subpopulations in 157 PCLD. Two populations with similar expression of macrophage markers and 158 comparable transcriptomic profiles, likely representative of the transcriptional 159 spectrum of resident healthy alveolar macrophages (AM) (Mould et al., 2021) were 160 combined for subsequent analysis (Figure 3a,b and Supplementary Figure 6a,b). We 161 identified three further small specialized AM subsets previously detected in healthy 162 individuals (Mould et al., 2021), characterized by high levels of proinflammatory 163 molecule expression, "Inflam AM", metal-binding metallothioneins, "MT-AM", or

interferon-stimulated genes "IFN stim AM". Proliferating macrophages were delineated
by high expression of a gene module representing the cellular proliferation response
(Chandran et al., 2022) (Figure 3a-d).

167 Monocyte-like cells are present in healthy airspaces, and suggested by trajectory 168 inference and increasing expression of macrophage marker genes over pseudotime 169 to differentiate into AM, implying constant trafficking of monocytes into the lung (Mould 170 et al., 2021). Consistent with this, we identified CD14, FCN1 expressing classical 171 monocytes (FCN1-Mono) (Mould et al., 2021; Wauters et al., 2021) characterized by 172 high levels of CCR2, the receptor for monocyte chemoattractant protein, suggestive 173 of recent recruitment from the peripheral blood (Auffray et al., 2009) (Figure 3c,d). A 174 second LGMN and SPP1 expressing subset (LGMN-Mono), recently identified as a rare population defined by expression of cell-matrix interaction genes in healthy 175 176 airspaces (Mould et al., 2021), was also present (Figure 3c,d). In contrast to acute 177 severe COVID-19 where proinflammatory monocytes and profibrotic SPP1, LGMN 178 expressing macrophages have been reported to be abundant (Liao et al., 2020; 179 Wendisch et al., 2021), monocytes represented a minor constituent of PCLD BAL. 180 Neither subset expressed high levels of inflammatory mediators (Figure 3c,d) and very 181 few cells expressed a gene signature characteristic of profibrotic macrophages 182 recently identified in idiopathic pulmonary fibrosis (Adams et al., 2020), (Figure 3e and Supplementary Figure 7a). 183

No differences in the relative proportions of any of the myeloid populations were evident between the two PCLD phenotypes (Figure 3f). Very few gene expression differences were detected between the two phenotypes by pseudobulk analysis of macrophage or monocyte subsets (Supplementary Table 2). Similar to the analysis of

the full dataset stratified by broad cell type, re-clustering macrophages to identify more
discrete sub-populations did not reveal transcriptomic differences between
inflammatory and fibrotic PCLD.

191 Single-cell differential gene expression analysis revealed weak enrichment for 192 immune response and cellular metabolism pathways in both groups (Supplementary Figure 7b,c). Minor enrichment for TGFβ-mediated signalling was evident for genes 193 194 expressed at higher levels in AM, Inflam-AM and FCN1-Mono in inflammatory PCLD 195 (Supplementary Figure 7b). Proinflammatory cytokines, T cell activation factors, SPP1 196 and TGF<sup>β</sup> were identified as statistically enriched upstream regulators of differentially 197 expressed genes in both monocyte populations in inflammatory PCLD 198 (Supplementary Figure 8a,b,d,e). However, as for analysis at the level of broad cell 199 types and refined T cell subsets, there was considerable overlap between molecules 200 predicted to drive gene expression differences in each PCLD phenotype 201 (Supplementary Figure 8c,f), suggesting that between group differential gene 202 expression in this analysis did not represent differential biology between radiological 203 patterns of disease.

#### 204 Highly related TCRs indicate antigen-specific immune responses in PCLD

To further evaluate T cell responses in PCLD we undertook single-cell TCR sequencing (scTCRseq) and compared the TCR repertoire in each radiological phenotype. We successfully obtained scTCRseq data for five fibrotic and three inflammatory cases. Increased T cell abundance in inflammatory PCLD may reflect increased numbers of unique T cell clones or increased expansion of individual clones. Expanded clonotypes identified by being present with a frequency of greater than one, were evident within the three major T cell subsets in both inflammatory and fibrotic

PCLD (Figure 4a). A greater proportion of CD4 TCM clones were expanded in the inflammatory phenotype, consistent with our observation of the higher abundance of this subset in this group. However, the proportion of expanded CD8 TEM and Treg clones was similar in both phenotypes (Figure 4b).

216 As T cell clonal expansion was evident in both PCLD phenotypes, we next sought to 217 identify related TCRs for each group based on the similarity of their antigen specificity-218 determining complementarity determining region (CDR)3 amino acid sequences, on 219 the premise that clusters of related TCRs recognize similar epitopes (details of the 220 analysis are provided in the methods). We hypothesized that the inflammatory cases 221 would exhibit more clustering than the fibrotic cases, given the trend towards a greater 222 proportion of expanded CD4 TCM clones and increased abundance of both CD4 TCM 223 and CD8 TEM in the inflammatory group. However, high levels of clustering were 224 evident in both inflammatory and fibrotic PCLD. In benchmarking, this level of 225 clustering was similar to that observed for expanded peripheral blood TCR clones 226 detected following non-severe SARS-CoV-2 infection, and exceeded that in non-227 expanded TCRs from non-infected individuals from the same cohort (Chandran et al., 228 2022; Milighetti et al., 2023) (Figure 4c,d). In both radiological groups of PCLD the 229 vast majority of clusters contained TCRs from multiple donors (Figure 4e) but there 230 was minimal sharing of identical CDR3 sequences between different individuals 231 (Supplementary Table 3). As a further comparison of inflammatory and fibrotic PCLD 232 T cell repertoires we clustered CDR3 amino acid sequences from both groups 233 together. Strikingly, most clusters contained TCRs from both inflammatory and fibrotic 234 samples and multiple donors, suggesting the presence of T cell clones that recognize 235 similar antigens across both phenotypes. A few small clusters composed uniquely of

either inflammatory or fibrotic PCLD TCRs were evident, indicative of subtledifferences between the two repertoires (Figure 4f).

238 The high level of relatedness between TCRs in PCLD is suggestive of antigen-specific 239 immune responses. We therefore sought to determine whether these repertoires were 240 enriched for T cells specific for SARS-CoV-2 by comparison to other common viruses. 241 Of the SARS-CoV-2-reactive TCRs identified in the VDJdb database, six were present 242 in TCR data from inflammatory PCLD and eight in fibrotic PCLD. None were identified 243 in equivalent sized healthy peripheral blood repertoires. However, fewer SARS-CoV-244 2-specific-TCRs were detected than Epstein-Barr virus (EBV)-specific or 245 cytomegalovirus (CMV)-specific sequences, indicating no enrichment for SARS-CoV-246 2-specific T cells at the site of disease. There was no enrichment for SARS-CoV-2-247 reactive or EBV-reactive TCRs in inflammatory compared to fibrotic PCLD. However, 248 CMV-specific TCRs were significantly enriched in the fibrotic group (Figure 4g). TCRs 249 found in clusters composed uniquely of either PCLD phenotype were not enriched for 250 known virus reactive-sequences (Supplementary Table 4).

## 251 DISCUSSION

252 We report the first comparative molecular analysis of cells sampled by bronchoalveolar 253 lavage from patients displaying either predominantly inflammatory or fibrotic 254 radiological sequelae following COVID-19. The bronchoalveolar pulmonary 255 environment of inflammatory PCLD was characterised by significantly increased 256 abundance of CD4 central memory and CD8 effector memory T cells compared to 257 fibrotic PCLD. Clustering of similar TCRs from different donors, far exceeding that 258 observed in healthy peripheral blood, was evident in both radiological phenotypes, 259 suggestive of an antigen-specific immune response localised to the lung. The 11

260 transcriptomes of post-COVID radiological inflammation and fibrosis were highly 261 similar for all bronchoalveolar cell types, dominated by cellular processes involved in 262 inflammatory and immune responses. We found no robust evidence of enhanced 263 activity of tissue damage or wound repair pathways in those with fibrotic radiological 264 changes. Although many cell type-specific differentially expressed genes were 265 identified between the two radiological phenotypes by single-cell methods, there were 266 no systematic differences in enriched biological pathways or their upstream regulators 267 among these differentially expressed genes. Furthermore, almost no differences in 268 gene expression between the fibrotic and the inflammatory groups were detected if 269 gene expression within cell types was aggregated by donor before differential analysis 270 (Squair et al., 2021). Our data lead us to propose that the two radiological phenotypes 271 represent distinct manifestations of a similar pathological process.

272 T cell infiltration has been a consistent finding in recent studies which have examined 273 the post-COVID-19 airspaces; almost exclusively within 3-6 months of the acute insult, 274 when radiological inflammation is more common than fibrosis (Cheon et al., 2021; 275 Gagiannis et al., 2023; Ravaglia et al., 2022; Vijayakumar et al., 2022). The cellular 276 proportions of our fibrotic PCLD samples, harvested at 9-12 months after acute illness, 277 were akin to those reported in BAL samples from healthy individuals, with 278 macrophages comprising greater than 80% and lymphocytes less than 15% of cells 279 (Mould et al., 2021; The BAL Cooperative Group Steering Committee, 1990). This is 280 in keeping with the reported repopulation of the airspaces by AM in the later stages of 281 COVID-19 acute respiratory distress syndrome (ARDS) (Wendisch et al., 2021). 282 Minimal data currently available for longitudinal samples obtained at approximately 283 one year post-infection also suggest a trajectory of gradual normalization of molecular

abnormalities and airspace cellular composition (Vijayakumar et al., 2022). 284 285 Nonetheless there is considerable interest in the apeutic intervention to expedite 286 resolution of subacute inflammation, to prevent progression to fibrosis with 287 concomitant irreversible tissue damage in susceptible individuals. Our findings 288 suggest therapies which target T cells, rather than anti-fibrotic agents could be 289 beneficial in PCLD, particularly in those with radiological inflammation. In support of 290 this premise, one small uncontrolled clinical study demonstrated improvement in 291 clinical symptoms, physiological parameters and radiological abnormalities, following 292 three weeks of corticosteroid treatment instituted approximately three months post-293 COVID-19 (Myall et al., 2021).

294 The bronchoalveolar TCR repertoire from both PCLD phenotypes exhibited high levels 295 of relatedness, suggestive of antigen-specific immune responses. In addition, the high 296 proportion of clusters containing TCRs from multiple donors suggests immune 297 responses against similar antigens, despite almost no sharing of identical TCR 298 sequences between different individuals. Aberrant immune responses to persistent 299 reservoirs of virus have been posited as drivers of post-acute sequelae of SARS-CoV-300 2 infection (Cheung et al., 2022; Merad et al., 2022; Stein et al., 2022). However, even 301 including all detected TCRs, to offset the inherent sparsity of single-cell data, there 302 was no enrichment for known SARS-CoV-2-specific T cell clones compared to TCRs 303 specific for other common viruses. Hence, based on the current compendium of 304 SARS-CoV-2-reactive TCRs (Bagaev et al., 2020), which may not be comprehensive, 305 there was no evidence for viral persistence at the site of disease in our cohort. A more 306 plausible hypothesis, given reports of cross-reactivity between SARS-CoV-2 and 307 human antigens (Nunez-Castilla et al., 2022; Vojdani and Kharrazian, 2020), is that

308 the PCLD TCR repertoire is directed against as yet unknown respiratory autoantigens.

309 Identifying the antigenic targets of the PCLD T cell repertoire may present 310 opportunities for more specific therapeutic interventions.

311 Pro-fibrotic macrophages have been implicated in the pathogenesis of severe COVID-312 19 ARDS, which has been associated with rapid onset pulmonary fibrosis, which 313 improves over time (Wendisch et al., 2021). Minimal interstitial fibrosis and the 314 presence of pro-fibrotic macrophages have also been reported in transbronchial lung 315 biopsies from a subset of individuals sampled at least 12 weeks after mild COVID-19 316 (Gagiannis et al., 2023). However, there was no difference between the frequency at 317 which mild fibrotic features were detected in the PCLD group and pre-pandemic 318 autopsy samples from individuals who had died of non-respiratory causes (Gagiannis 319 et al., 2023). In our study, which encompassed a broad range of severity of acute 320 disease, including several individuals with COVID-19 ARDS, the phenotype of myeloid 321 cells in both radiological groups was consistent with the spectrum of macrophages 322 and monocytes found in healthy airspaces (Mould et al., 2021); with no convincing 323 evidence for exaggerated activity of pro-fibrogenic pathways. The heterogeneity of 324 disease phenotype and longer time interval after acute illness at which our cohort were 325 sampled may account for this discrepancy. Of note, CMV-specific T cell clones were 326 enriched in individuals with fibrotic PCLD, consistent with the repeated association of 327 CMV with pulmonary fibrosis (Moore and Moore, 2015). However, this observation is 328 of uncertain significance, given the lack of existing evidence for a direct role for CMV 329 in causing human pulmonary fibrosis (Moore and Moore, 2015).

Our study has some limitations. We acknowledge a small sample size, heterogeneouspatient cohort, and lack of specimens for histological correlation and orthogonal

332 validation of our single-cell data. Our findings provide early mechanistic insights, are 333 hypothesis-generating and will require further validation in larger cohorts. Those with 334 fibrotic radiological appearances were sampled later after acute disease than those 335 with radiological inflammation. Ideally, we would have more closely matched the 336 interval after acute COVID-19 at which both groups were sampled. However, the 337 introduction of dexamethasone treatment early in the second wave of the pandemic 338 was coincident with reduced numbers of individuals with persistent respiratory 339 symptoms and radiological abnormalities. Consequently, we extended the interval 340 after acute illness within which individuals were eligible for sampling. Since our aim 341 was to evaluate whether single-cell profiling of the bronchoalveolar environment of 342 individuals with inflammatory and fibrotic radiological patterns of PCLD at the time of 343 sampling would reveal different immunopathogenic mechanisms for these 344 phenotypes, we believe our approach remains valid. It also provided invaluable 345 opportunities to assess respiratory tract samples from the later stages of PCLD which 346 have received minimal attention to date. This was a cross-sectional evaluation of 347 bronchoalveolar immune cells, which did not allow assessment of the temporal 348 evolution of the immune response in PCLD within individuals. Future studies 349 encompassing longitudinal monitoring of the bronchoalveolar environment might 350 provide important insights into the molecular mechanisms driving resolution and 351 whether this trajectory is a universal phenomenon for both inflammation and fibrosis 352 following COVID-19. Augmented neutrophil-associated immune signatures have been 353 described in plasma and nasal samples in individuals with post-COVID pulmonary 354 sequelae, however, neutrophils were not detected in our samples, possibly due to the 355 Chromium 10x Genomics sample processing conditions used at the time of our

356 analysis (George et al., 2022). Finally, due to technical limitations because of the low 357 numbers of T cells present in BAL samples, we were unable to obtain TCR data for 358 two inflammatory cases. Nonetheless, our data provide strong support for the notion 359 that the TCR repertoire of PCLD reflects antigen-directed immune responses. 360 Our observations that inflammatory PCLD is characterised by airway T cell infiltration 361 and that antigen-specific T cell responses are evident in both radiological phenotypes, 362 highlight opportunities for early intervention with therapies targeting T cells. 363 Understanding the timing and duration of intervention, stratification of those at high 364 risk of irreversible tissue damage and the potential use of more targeted T cell 365 immunomodulators all merit further investigation.

366 **Метнорs** 

#### 367 Ethics statement

368 The study was approved by the North London Research Ethics Committee 369 (13/LO/0900). Written informed consent was obtained from all participants. Subject 370 identifiers were not known to anyone outside the research group.

#### 371 Study design and eligibility

372 Immune cells from the site of disease were obtained from adults (≥18 years) 373 undergoing bronchoscopy for clinical investigation of persistent respiratory symptoms 374 and CT abnormalities consistent with pulmonary inflammation (n=5) or fibrosis (n=5) 375 at least 12 weeks after acute COVID-19, confirmed by a positive SARS-CoV-2 376 antibody or polymerase chain reaction (PCR) test. PCLD was defined in this cohort 377 based on the following criteria: 1) new, persistent respiratory symptoms following 378 SARS-CoV-2 infection at least 12 weeks previously, 2) post-COVID-19 residual lung 379 abnormalities with more than 10% lung involvement on CT and 3) breathlessness in 16

380 keeping with the CT changes and not explained by other causes. Thoracic CT scans 381 were classified as predominantly inflammatory or fibrotic by consensus opinion of the 382 ILD multi-disciplinary team, which included thoracic radiologists with ILD expertise. 383 Radiological inflammation was defined as consolidation or ground glass opacities 384 without reticulation or parenchymal distortion and fibrosis defined as reticulation or 385 traction bronchiectasis. Individuals with evidence of ILD prior to COVID-19, those with 386 coincident malignancy, human immunodeficiency virus infection, bacterial, viral or 387 fungal respiratory tract infection, taking immunomodulatory therapy, or unable to give 388 informed consent were excluded.

#### 389 Isolation of bronchoalveolar cells

390 Flexible fibreoptic bronchoscopy was used to obtain BAL samples by instillation of 391 180-240 ml of warmed normal saline into a lung segment affected by the predominant 392 radiological abnormality. Aspirated BAL fluid was cooled to 4°C and filtered through a 393 cell strainer to remove particulate debris before centrifugation. After removal of the 394 supernatant, cells were resuspended in PBS. Cell count and viability were determined 395 by Trypan blue staining and erythrocytes removed where indicated, using ammoniumchloride-potassium red cell lysis buffer. Cells were resuspended at 2 x10<sup>6</sup> per ml for 396 397 immediate downstream processing.

#### 398 scRNAseq and scTCRseq library preparation and sequencing

399 20,000 cells per sample were loaded on to the Chromium controller (10x Genomics) 400 to generate single-cell gel beads in emulsion (GEMs). Single-cell partitioning, reverse 401 transcription, cDNA amplification and library construction were performed using the 402 Chromium Single-cell 5' Reagent kits v1.1 and v2 (10x Genomics) according to the 403 manufacturer's instructions. T cell receptor (TCR) V(D)J segments were enriched from

amplified cDNA using Chromium Single-Cell V(D)J Enrichment kits v1.1 and v2 (10x
Genomics) per the manufacturer's protocol. Libraries were quality checked and
quantified using the High Sensitivity DNA kit and 4200 TapeStation (Agilent).
Sequencing was performed in paired end mode with SP100, P2 and P3 flow cells (100
cycles) using NovaSeq 6000 and NextSeq 2000 systems (Illumina).

#### 409 scRNAseq data analysis

#### 410 Cell Ranger

Raw sequencing files were demultiplexed using BCL Convert v3.7.5 (Illumina) or Cell Ranger version 6.1.1 using the "mkfastq" script. Transcript alignment and quantitation against the GRCh38 human genome assembly was performed using Cell Ranger "multi" for samples with gene expression and T cell VDJ data or Cell Ranger "count" for samples with gene expression data only.

## 416 **Quality control**

Initial processing of Cell Ranger output data was performed using Seurat v4.1.0 in R
4.1.1 (Stuart et al., 2019). Cell Ranger output files were loaded using the "Read10x"
function. Low quality cells with less than 200 or more than 6000 unique features or
more than 10% mitochondrial genes were removed; 57,712 cells were retained for
downstream analysis.

#### 422 Normalization, feature selection and integration

For each sample data were normalized and highly variable genes selected before
integration to remove donor-specific batch effects, using the following Seurat functions
implemented with default parameters; NormalizeData (normalization.method =
"LogNormalize), FindVariableFeatures (selection.method = "vst", nfeatures = 2000),
IntegrateData (anchorset = immune.anchors).

## 428 Dimensional reduction, clustering and annotation

429 Data were then scaled using the Seurat ScaleData function and dimensional reduction 430 achieved by principal component analysis (PCA) of the most variable genes using 431 RunPCA. The first 25 principal components (PCs) were used to generate the Uniform 432 Manifold Approximation and Projection (UMAP) for two-dimensional visualization of 433 the cells (RunUMAP) and for nearest neighbor graph construction (FindNeighbors) 434 and Louvain clustering (FindClusters) using a resolution of 0.8. This clustering 435 resolution was selected on the basis that it successfully partitioned single-cell 436 transcriptomes into the broad cell types expected to be present in BAL. Automatic cell 437 type annotation of clusters was performed with the Semi-supervised Category 438 Identification and Assignment (SCINA) R package using gene signatures from the 439 Azimuth human lung v1 reference 440 (https://azimuth.hubmapconsortium.org/references/#Human-Lungv1) (Travaglini et 441 al., 2020; Zhang et al., 2019). Additional manual annotation of dendritic cells and B 442 cells was performed using literature-based markers (Cheng et al., 2021; Glass et al., 443 2020; Villani et al., 2017). A population with low numbers of genes, which could not be 444 annotated by automatic or manual methods and likely represents empty droplets 445 containing ambient RNA, was removed after clustering. To validate our clustering and 446 annotation strategy, we visualized the expression of canonical or published marker 447 genes for each cell type using a dot plot (Adams et al., 2020; Cheng et al., 2021; David 448 et al., 2021; Davies et al., 2013; Davis and Wypych, 2021; Gardell and Parker, 2017; 449 Glass et al., 2020; Murray and Wynn, 2011; Tsyklauri et al., 2023; van Aalderen et al., 450 2021; Villani et al., 2017).

## 451 T cell and macrophage re-clustering

452 For separate analyses of T cells only and macrophages only, cells in the relevant 453 clusters were subsetted and normalization, variable feature selection, integration, data 454 scaling, PCA, UMAP generation and Louvain clustering repeated. The first 25 PCs 455 were used for data integration and clustering for both macrophages and T cells. The 456 k.weight parameter was reduced to 70 for the T cell integration step in order to take 457 account of the low number of cells in sample 12. Resolution 0.4 was used for re-458 clustering T cells and resolution 0.7 for re-clustering macrophages. T cell subsets were 459 annotated using SCINA with Azimuth human PBMC reference marker genes 460 https://azimuth.hubmapconsortium.org/references/#Human-PBMC and additional 461 published CD4 T cell signatures (Cano-Gamez et al., 2020; Zhang et al., 2019). 462 Macrophages were annotated using SCINA with Azimuth human lung v1 reference 463 marker genes and additional signatures derived from published literature (Mould et al., 464 2021; Travaglini et al., 2020; Wendisch et al., 2021; Zhang et al., 2019).

#### 465 **Calculation of gene module scores**

The Seurat function AddModuleScore was used to calculate enrichment of a cyclin D1 (CCND1) regulated module representing the cellular proliferation response (Chandran et al., 2022) and a profibrotic macrophage gene module derived from idiopathic pulmonary fibrosis (Adams et al., 2020). Module scores represent the average expression of gene signatures of interest with subtraction of the average expression of control gene sets randomly selected from each expression bin which contains a module gene.

#### 473 Differential gene expression and differential cell type abundance analysis

474 For comparison of gene expression in individual cells (single-cell method) the scran R20

475 package findMarkers function was implemented using the following settings: test.type 476 = "wilcox", direction = "up", pval.type = "all", lfc = 0. For identification of cell type 477 (cluster) marker genes, sample was included as a blocking factor. Genes with an 478 adjusted p-value <0.05 were considered significantly differentially expressed. For 479 comparison of gene expression at cell type level (pseudobulk method) the scuttle R 480 package aggregateAcrossCells function was used to aggregate counts for each cell 481 type within each sample to create "pseudobulks" before statistical analysis was 482 performed. Differentially expressed genes were identified using the scran 483 pseudoBulkDGE function, implementing the edgeR negative binomial generalized 484 linear model with quasi-likelihood F test (GLM-QLF) (Robinson et al., 2010). Genes 485 with an adjusted p-value <0.05 were considered significant. Differences in cell type 486 abundance between inflammatory and fibrotic PCLD were identified using the edgeR 487 GLM-QLF test implemented by scran. Cell types with an adjusted p-value <0.05 were 488 considered differentially abundant.

#### 489 Pathway enrichment analysis

490 The biological pathways represented by differentially expressed genes were identified 491 by Reactome pathway enrichment analysis using XGR as previously described (Fang 492 et al., 2016; Turner et al., 2021). For visualization, 15 pathway groups were identified 493 by hierarchical clustering of Jaccard indices to quantify similarity between the gene 494 compositions of each pathway. For each group the pathway term with the largest 495 number of annotated genes was then selected as representative of the enriched 496 biology.

#### 497 Upstream regulator analysis

498 Ingenuity Pathway Analysis (Qiagen) was used to identify upstream transcriptional 21

499 regulation of differentially expressed genes. This analysis was restricted to molecules 500 annotated with the following functions: cytokine, growth factor, transmembrane 501 receptor, kinase and transcriptional regulator, representing the canonical components 502 of pathways which execute transcriptional reprogramming in immune and tissue repair 503 responses. Enriched molecules with an adjusted p-value <0.05 were considered 504 statistically significant. Area-proportional Venn diagrams visualizing the overlap 505 between molecules predicted to regulate cell type-specific differentially expressed 506 genes in inflammatory PCLD and fibrotic PCLD were generated using BioVenn 507 (Hulsen et al., 2008).

#### 508 TCR quantitation and CDR3 clustering

509 TCR sequences were assembled by the Cell Ranger multipipeline (v6.1.1). For single-510 cell TCR analysis, TCR clonotype abundance information was imported directly from 511 Cell Ranger "filtered contig annotations" output files, where clonotype identity was 512 determined as cells with identical V(D)J and CDR3 sequences. Clonotypes were 513 assigned to single cells using index barcodes. TCRs found more than once were 514 defined as expanded. Density plots were calculated using the UMAP coordinates of 515 every expanded cell with a detectable TCR using geom density 2d from the ggplot2 516 package.

517 For clustering analysis of each PCLD phenotype individually, all detected alpha and 518 beta chain sequences in the inflammatory samples were included, to take account of 519 the sparsity of single-cell data. Including larger numbers of TCR sequences leads to 520 more clustering (Madi et al., 2017); fibrotic PCLD and control group TCR sequences 521 were therefore subsampled to match the number of sequences in the inflammatory 522 PCLD group, which contained the smallest repertoire. We included expanded

523 peripheral blood TCRs from individuals with non-severe SARS-CoV-2 infection as a 524 positive control dataset known to exhibit high levels of clustering and non-expanded 525 TCRs randomly selected from uninfected individuals from this same cohort, as a 526 negative control dataset, not expected to cluster highly (Chandran et al., 2022; 527 Milighetti et al., 2023). For the combined analysis of both PCLD phenotypes all detected CDR3 sequences were included. TCR clustering was performed as 528 529 previously described (Joshi et al., 2019). Briefly, CDR3 amino acid sequences were 530 deconstructed into overlapping series of contiguous triplets. Pairwise similarity 531 between two CDR3s was calculated as the normalized string (triplet) kernel using the 532 Kernlab R package (Karatzoglou et al., 2004). The resulting TCR similarity matrix was 533 converted into a network diagram in which CDR3s with a pairwise similarity above a 534 designated threshold were connected by an edge using the iGraph R package (Csardi 535 and Nepusz, 2006). We visualized thresholds at which PCLD TCRs exhibited the 536 largest increase in the percentage of TCRs clustering compared to negative control 537 TCR data for clustering of PCLD groups individually. For combined clustering of 538 inflammatory and fibrotic PCLD we visualized thresholds at which the largest clusters 539 composed uniquely of one phenotype were present.

#### 540 Virus specific TCR enrichment analysis

541 TCRs annotated for SARS-CoV-2, CMV and EBV were obtained from the VDJdb 542 database (Bagaev et al., 2020) (https://vdjdb.cdr3.net/), accessed on 1st November 543 2021. The number of annotated sequences for each virus in VDJdb either matching 544 or not matching TCRs detected in inflammatory and fibrotic PCLD or the negative 545 controls was used to calculate the odds ratio (Fisher's exact test) for enrichment of 546 virus-specific TCRs in each group.

#### 547 Data availability

- 548 scRNAseq and scTCRseq data will be available in the Gene Expression Omnibus
- 549 (GEO) database at the time of peer-reviewed publication of the manuscript under
- 550 accession number GSE228236.

#### 551 **ACKNOWLEDGEMENTS**

- 552 We thank Dr Arjun Nair for oversight of the ILD MDT discussions to classify radiological
- changes as predominantly inflammatory or fibrotic and for identification of lung 553
- 554 segments to be targeted for sampling by BAL.

#### 555 REFERENCES

- 556 Adams TS, Schupp JC, Poli S, Ayaub EA, Neumark N, Ahangari F, Chu SG, Raby 557 BA, Deluliis G, Januszyk M, Duan Q, Arnett HA, Siddigui A, Washko GR, 558 Homer R, Yan X, Rosas IO, Kaminski N. 2020. Single-cell RNA-seg reveals 559 ectopic and aberrant lung-resident cell populations in idiopathic pulmonary 560 fibrosis. Sci Adv 6:eaba1983. doi:10.1126/sciadv.aba1983
- 561 Auffray C, Sieweke MH, Geissmann F. 2009. Blood monocytes: development, 562 heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 563 27:669–692. doi:10.1146/annurev.immunol.021908.132557
- 564 Bagaev DV, Vroomans RMA, Samir J, Stervbo U, Rius C, Dolton G, Greenshields-Watson A, Attaf M, Egorov ES, Zvyagin IV, Babel N, Cole DK, Godkin AJ, 565 566 Sewell AK, Kesmir C, Chudakov DM, Luciani F, Shugay M. 2020. VDJdb in 567 2019: database extension, new analysis infrastructure and a T-cell receptor 568 motif compendium. Nucleic Acids Res 48:D1057–D1062. 569 doi:10.1093/nar/gkz874
- 570 Cano-Gamez E, Soskic B, Roumeliotis TI, So E, Smyth DJ, Baldrighi M, Willé D, 571 Nakic N, Esparza-Gordillo J, Larminie CGC, Bronson PG, Tough DF, Rowan 572 WC, Choudhary JS, Trynka G. 2020. Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4+ T cells to cytokines. Nat 573 Commun 11:1801. doi:10.1038/s41467-020-15543-v 574
- 575 Chandran A, Rosenheim J, Nageswaran G, Swadling L, Pollara G, Gupta RK, Burton 576 AR, Guerra-Assunção JA, Woolston A, Ronel T, Pade C, Gibbons JM, Sanz-577 Magallon Duque De Estrada B, Robert de Massy M, Whelan M, Semper A, 578 Brooks T, Altmann DM, Boyton RJ, McKnight Á, Captur G, Manisty C, Treibel 579 TA, Moon JC, Tomlinson GS, Maini MK, Chain BM, Noursadeghi M, 580 COVIDsortium Investigators. 2022. Rapid synchronous type 1 IFN and virus-
- 581 specific T cell responses characterize first wave non-severe SARS-CoV-2 582 infections. Cell Rep Med 3:100557. doi:10.1016/j.xcrm.2022.100557
- 583 Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Yu, Qin S, Zhang L, Ouyang H, Du P,

584	Jiang L, Zhang B, Yang Yue, Wang X, Ren X, Bei J-X, Hu X, Bu Z, Ji J,
585	Zhang Z. 2021. A pan-cancer single-cell transcriptional atlas of tumor
586	infiltrating myeloid cells. <i>Cell</i> <b>184</b> :792-809.e23. doi:10.1016/j.cell.2021.01.010
587	Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, Wang Z, Wei X, Tang J, Li
588	Y, Marlow H, Hughes S, Hammel L, Cox TM, Goddery E, Ayasoufi K,
589	Weiskopf D, Boonyaratanakornkit J, Dong H, Li H, Chakraborty R, Johnson
590	AJ, Edell E, Taylor JJ, Kaplan MH, Sette A, Bartholmai BJ, Kern R, Vassallo
591	R, Sun J. 2021. Immune signatures underlying post-acute COVID-19 lung
592	sequelae. <i>Sci Immunol</i> <b>6</b> :eabk1741. doi:10.1126/sciimmunol.abk1741
593	Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, Tan B, Tay ZEA, Wan WY,
594	Chen EX, Nerurkar SN, Loong S, Cheow PC, Chan CY, Koh YX, Tan TT,
595	Kalimuddin S, Tai WMD, Ng JL, Low JG-H, Yeong J, Lim KH. 2022. Residual
596	SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five
597	recovered patients with COVID-19. <i>Gut</i> <b>71</b> :226–229. doi:10.1136/gutjnl-2021-
598	324280
599 600	Csardi G, Nepusz T. 2006. The igraph software package for complex network research. <i>Complex Syst</i> <b>1695</b> :1–9.
601	David G, Willem C, Legrand N, Djaoud Z, Mérieau P, Walencik A, Guillaume T,
602	Gagne K, Chevallier P, Retière C. 2021. Deciphering the biology of KIR2DL3+
603	T lymphocytes that are associated to relapse in haploidentical HSCT. <i>Sci Rep</i>
604	<b>11</b> :15782. doi:10.1038/s41598-021-95245-7
605	Davies LC, Jenkins SJ, Allen JE, Taylor PR. 2013. Tissue-resident macrophages.
606	<i>Nat Immunol</i> <b>14</b> :986–995. doi:10.1038/ni.2705
607 608	Davis JD, Wypych TP. 2021. Cellular and functional heterogeneity of the airway epithelium. <i>Mucosal Immunol</i> <b>14</b> :978–990. doi:10.1038/s41385-020-00370-7
609	Fabbri L, Moss S, Khan FA, Chi W, Xia J, Robinson K, Smyth AR, Jenkins G,
610	Stewart I. 2023. Parenchymal lung abnormalities following hospitalisation for
611	COVID-19 and viral pneumonitis: a systematic review and meta-analysis.
612	<i>Thorax</i> 78:191–201. doi:10.1136/thoraxjnl-2021-218275
613	Fang H, Knezevic B, Burnham KL, Knight JC. 2016. XGR software for enhanced
614	interpretation of genomic summary data, illustrated by application to
615	immunological traits. <i>Genome Med</i> 8:129. doi:10.1186/s13073-016-0384-y
616	Gagiannis D, Hackenbroch C, Bloch W, Zech F, Kirchhoff F, Djudjaj S, von Stillfried
617	S, Bülow R, Boor P, Steinestel K. 2023. Clinical, Imaging, and
618	Histopathological Features of Pulmonary Sequelae Following Mild COVID-19.
619	<i>Am J Respir Crit Care Med</i> . doi:10.1164/rccm.202302-0285LE
620	Gardell JL, Parker DC. 2017. CD40L is transferred to antigen-presenting B cells
621	during delivery of T-cell help. <i>Eur J Immunol</i> <b>47</b> :41–50.
622	doi:10.1002/eji.201646504
623	George PM, Reed A, Desai SR, Devaraj A, Faiez TS, Laverty S, Kanwal A, Esneau
624	C, Liu MKC, Kamal F, Man WD-C, Kaul S, Singh S, Lamb G, Faizi FK,
625	Schuliga M, Read J, Burgoyne T, Pinto AL, Micallef J, Bauwens E, Candiracci
626	J, Bougoussa M, Herzog M, Raman L, Ahmetaj-Shala B, Turville S, Aggarwal
627	A, Farne HA, Dalla Pria A, Aswani AD, Patella F, Borek WE, Mitchell JA,
628	Bartlett NW, Dokal A, Xu X-N, Kelleher P, Shah A, Singanayagam A. 2022. A
629	persistent neutrophil-associated immune signature characterizes post-COVID-
	25

630 19 pulmonary sequelae. Sci Transl Med 14:eabo5795. 631 doi:10.1126/scitransImed.abo5795 632 Glass DR, Tsai AG, Oliveria JP, Hartmann FJ, Kimmey SC, Calderon AA, Borges L, 633 Glass MC, Wagar LE, Davis MM, Bendall SC. 2020. An Integrated Multi-omic 634 Single-Cell Atlas of Human B Cell Identity. Immunity 53:217-232.e5. 635 doi:10.1016/j.immuni.2020.06.013 636 Hulsen T, de Vlieg J, Alkema W. 2008. BioVenn - a web application for the 637 comparison and visualization of biological lists using area-proportional Venn 638 diagrams. BMC Genomics 9:488. doi:10.1186/1471-2164-9-488 639 Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, 640 Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Sunderland MW, Jamal-641 642 Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-643 Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, 644 McGranahan N, Swanton C, TRACERx consortium, Quezada SA, Chain B. 645 2019. Spatial heterogeneity of the T cell receptor repertoire reflects the 646 mutational landscape in lung cancer. *Nat Med* 25:1549–1559. 647 doi:10.1038/s41591-019-0592-2 648 Karatzoglou A, Smola A, Hornik K, Zeileis A. 2004. kernlab - An S4 Package for 649 Kernel Methods in R. J Stat Softw 11:1-20. doi:10.18637/jss.v011.i09 650 Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L, 651 Amit I, Zhang S, Zhang Z. 2020. Single-cell landscape of bronchoalveolar 652 immune cells in patients with COVID-19. Nat Med 26:842-844. 653 doi:10.1038/s41591-020-0901-9 654 Madi A, Poran A, Shifrut E, Reich-Zeliger S, Greenstein E, Zaretsky I, Arnon T, 655 Laethem FV, Singer A, Lu J, Sun PD, Cohen IR, Friedman N. 2017. T cell 656 receptor repertoires of mice and humans are clustered in similarity networks 657 around conserved public CDR3 sequences. eLife 6:e22057. 658 doi:10.7554/eLife.22057 659 Mehta P, Rosas IO, Singer M. 2022. Understanding post-COVID-19 interstitial lung 660 disease (ILD): a new fibroinflammatory disease entity. Intensive Care Med 661 **48**:1803–1806. doi:10.1007/s00134-022-06877-w 662 Merad M, Blish CA, Sallusto F, Iwasaki A. 2022. The immunology and 663 immunopathology of COVID-19. Science 375:1122-1127. 664 doi:10.1126/science.abm8108 665 Milighetti M, Peng Y, Tan C, Mark M, Nageswaran G, Byrne S, Ronel T, Peacock T, 666 Mayer A, Chandran A, Rosenheim J, Whelan M, Yao X, Liu G, Felce SL, 667 Dong T, Mentzer AJ, Knight JC, Balloux F, Greenstein E, Reich-Zeliger S, 668 Pade C, Gibbons JM, Semper A, Brooks T, Otter A, Altmann DM, Boyton RJ, 669 Maini MK, McKnight A, Manisty C, Treibel TA, Moon JC, Noursadeghi M, 670 Chain B. 2023. Large clones of pre-existing T cells drive early immunity 671 against SARS-COV-2 and LCMV infection. iScience 26. 672 doi:10.1016/j.isci.2023.106937 673 Moore BB, Moore TA. 2015. Viruses in Idiopathic Pulmonary Fibrosis. Etiology and 674 Exacerbation. Ann Am Thorac Soc 12 Suppl 2:S186-192. 675 doi:10.1513/AnnalsATS.201502-088AW 26

676 Mould KJ, Moore CM, McManus SA, McCubbrey AL, McClendon JD, Griesmer CL, 677 Henson PM, Janssen WJ. 2021. Airspace Macrophages and Monocytes Exist 678 in Transcriptionally Distinct Subsets in Healthy Adults. Am J Respir Crit Care 679 Med 203:946-956. doi:10.1164/rccm.202005-1989OC 680 Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage 681 subsets. Nat Rev Immunol 11:723-737. doi:10.1038/nri3073 682 Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, Preston R, 683 Thillai M. Dewar A. Molyneaux PL. West AG. 2021. Persistent Post-COVID-19 684 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. 685 Ann Am Thorac Soc 18:799–806. doi:10.1513/AnnalsATS.202008-1002OC 686 Nouno T, Okamoto M, Ohnishi K, Kaieda S, Tominaga M, Zaizen Y, Ichiki M, 687 Momosaki S, Nakamura M, Fujimoto K, Fukuoka J, Shimizu S, Komohara Y, 688 Hoshino T. 2019. Elevation of pulmonary CD163 + and CD204 + 689 macrophages is associated with the clinical course of idiopathic pulmonary 690 fibrosis patients. J Thorac Dis 11. doi:10.21037/jtd.2019.09.03 691 Nunez-Castilla J, Stebliankin V, Baral P, Balbin CA, Sobhan M, Cickovski T, Mondal 692 AM, Narasimhan G, Chapagain P, Mathee K, Siltberg-Liberles J. 2022. 693 Potential Autoimmunity Resulting from Molecular Mimicry between SARS-694 CoV-2 Spike and Human Proteins. Viruses 14:1415. doi:10.3390/v14071415 695 Ravaglia C. Doglioni C. Chilosi M. Piciucchi S. Dubini A. Rossi G. Pedica F. Puglisi 696 S, Donati L, Tomassetti S, Poletti V. 2022. Clinical, radiological and 697 pathological findings in patients with persistent lung disease following SARS-698 CoV-2 infection. Eur Respir J 60:2102411. doi:10.1183/13993003.02411-2021 699 Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for 700 differential expression analysis of digital gene expression data. Bioinforma 701 Oxf Engl 26:139–140. doi:10.1093/bioinformatics/btp616 702 Squair JW, Gautier M, Kathe C, Anderson MA, James ND, Hutson TH, Hudelle R, 703 Qaiser T, Matson KJE, Barraud Q, Levine AJ, La Manno G, Skinnider MA, 704 Courtine G. 2021. Confronting false discoveries in single-cell differential 705 expression. Nat Commun 12:5692. doi:10.1038/s41467-021-25960-2 706 Stein SR, Ramelli SC, Grazioli A, Chung J-Y, Singh M, Yinda CK, Winkler CW, Sun 707 J, Dickey JM, Ylaya K, Ko SH, Platt AP, Burbelo PD, Quezado M, Pittaluga S, 708 Purcell M, Munster VJ, Belinky F, Ramos-Benitez MJ, Boritz EA, Lach IA, 709 Herr DL, Rabin J, Saharia KK, Madathil RJ, Tabatabai A, Soherwardi S, 710 McCurdy MT, NIH COVID-19 Autopsy Consortium, Peterson KE, Cohen JI, de 711 Wit E, Vannella KM, Hewitt SM, Kleiner DE, Chertow DS. 2022. SARS-CoV-2 712 infection and persistence in the human body and brain at autopsy. Nature 713 612:758–763. doi:10.1038/s41586-022-05542-y 714 Stewart I, Jacob J, George PM, Molyneaux PL, Porter JC, Allen RJ, Aslani S, Baillie 715 JK, Barratt SL, Beirne P, Bianchi SM, Blaikley JF, Chalmers JD, Chambers 716 RC, Chaudhuri N, Coleman C, Collier G, Denneny EK, Docherty A, Elneima 717 O, Evans RA, Fabbri L, Gibbons MA, Gleeson FV, Gooptu B, Greening NJ, 718 Guillen Guio B, Hall IP, Hanley NA, Harris V, Harrison EM, Heightman M, 719 Hillman TE, Horsley A, Houchen-Wolloff L, Jarrold I, Johnson SR, Jones MG, 720 Khan F, Lawson R, Leavy O, Lone N, Marks M, McAuley H, Mehta P, Parekh 721 D, Piper Hanley K, Platé M, Pearl J, Poinasamy K, Quint JK, Raman B,

722	Richardson M, Rivera-Ortega P, Saunders L, Saunders R, Semple MG,	
723	Sereno M, Shikotra A, Simpson AJ, Singapuri A, Smith DJ, Spears M,	
724	Spencer LG, Stanel S, Thickett D, Thompson AAR, Thorpe M, Walsh SL,	
725	Walker S, Weatherley ND, Weeks M, Wild JM, Wootton DG, Brightling CE, Ho	
726	L-P, Wain LV, Jenkins RG. 2022. Residual Lung Abnormalities Following	
727	COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID Study.	
728	Am J Respir Crit Care Med. doi:10.1164/rccm.202203-0564OC	
729	Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y,	
730	Stoeckius M, Smibert P, Satija R. 2019. Comprehensive Integration of Single-	
731	Cell Data. <i>Cell</i> <b>177</b> :1888-1902.e21. doi:10.1016/j.cell.2019.05.031	
732 733 734 735	The BAL Cooperative Group Steering Committee. 1990. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. <i>Am Rev Respir Dis</i> <b>141</b> :S169-202. doi:10.1164/ajrccm/141.5_Pt_2.S169	
736 737 738 739 740	Travaglini KJ, Nabhan AN, Penland L, Sinha R, Gillich A, Sit RV, Chang S, Conley SD, Mori Y, Seita J, Berry GJ, Shrager JB, Metzger RJ, Kuo CS, Neff N, Weissman IL, Quake SR, Krasnow MA. 2020. A molecular cell atlas of the human lung from single-cell RNA sequencing. <i>Nature</i> 587:619–625. doi:10.1038/s41586-020-2922-4	
741	Tsyklauri O, Chadimova T, Niederlova V, Kovarova J, Michalik J, Malatova I,	
742	Janusova S, Ivashchenko O, Rossez H, Drobek A, Vecerova H, Galati V,	
743	Kovar M, Stepanek O. 2023. Regulatory T cells suppress the formation of	
744	potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2. <i>eLife</i>	
745	<b>12</b> :e79342. doi:10.7554/eLife.79342	
746	Turner CT, Brown J, Shaw E, Uddin I, Tsaliki E, Roe JK, Pollara G, Sun Y, Heather	
747	JM, Lipman M, Chain B, Noursadeghi M. 2021. Persistent T Cell Repertoire	
748	Perturbation and T Cell Activation in HIV After Long Term Treatment. <i>Front</i>	
749	Immunol <b>12</b> :634489. doi:10.3389/fimmu.2021.634489	
750	van Aalderen MC, van Lier RAW, Hombrink P. 2021. How to Reliably Define Human	
751	CD8+ T-Cell Subsets: Markers Playing Tricks. <i>Cold Spring Harb Perspect Biol</i>	
752	<b>13</b> :a037747. doi:10.1101/cshperspect.a037747	
753	Vijayakumar B, Boustani K, Ogger PP, Papadaki A, Tonkin J, Orton CM, Ghai P,	
754	Suveizdyte K, Hewitt RJ, Desai SR, Devaraj A, Snelgrove RJ, Molyneaux PL,	
755	Garner JL, Peters JE, Shah PL, Lloyd CM, Harker JA. 2022. Immuno-	
756	proteomic profiling reveals aberrant immune cell regulation in the airways of	
757	individuals with ongoing post-COVID-19 respiratory disease. <i>Immunity</i>	
758	55:542-556.e5. doi:10.1016/j.immuni.2022.01.017	
759	Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, Griesbeck M,	
760	Butler A, Zheng S, Lazo S, Jardine L, Dixon D, Stephenson E, Nilsson E,	
761	Grundberg I, McDonald D, Filby A, Li W, De Jager PL, Rozenblatt-Rosen O,	
762	Lane AA, Haniffa M, Regev A, Hacohen N. 2017. Single-cell RNA-seq reveals	
763	new types of human blood dendritic cells, monocytes, and progenitors.	
764	<i>Science</i> <b>356</b> :eaah4573. doi:10.1126/science.aah4573	
765	Vojdani A, Kharrazian D. 2020. Potential antigenic cross-reactivity between SARS-	
766	CoV-2 and human tissue with a possible link to an increase in autoimmune	
767	diseases. <i>Clin Immunol</i> <b>217</b> :108480. doi:10.1016/j.clim.2020.108480	
	28	

medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287759; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license . Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID lung disease

- 768 Wauters E, Van Mol P, Garg AD, Jansen S, Van Herck Y, Vanderbeke L, Bassez A, Boeckx B, Malengier-Devlies B, Timmerman A, Van Brussel T, Van Buyten T, 769 Schepers R, Heylen E, Dauwe D, Dooms C, Gunst J, Hermans G, 770 771 Meersseman P. Testelmans D. Yserbyt J. Teipar S. De Wever W. Matthys P. 772 Neyts J, Wauters J, Qian J, Lambrechts D. 2021. Discriminating mild from 773 critical COVID-19 by innate and adaptive immune single-cell profiling of 774 bronchoalveolar lavages. Cell Res 31:272-290. doi:10.1038/s41422-020-775 00455-9
- 776 Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, Mache C, 777 Chua RL, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller AL, 778 Pascual-Reguant A, Mothes R, Bülow RD, Schulze J, Leipold AM, Djudjaj S, 779 Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Baßler K, 780 Conrad Claudia, Aschenbrenner AC, Sawitzki B, Landthaler M, Wyler E, Horst 781 D. Deutsche COVID-19 OMICS Initiative (DeCOI), Hippenstiel S, Hocke A, Heppner FL, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault 782 783 C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, 784 Schultze JL, Radbruch H, Ochs M, Eils R, Müller-Redetzky H, Hauser AE, Luecken MD, Theis FJ, Conrad Christian, Wolff T, Boor P, Selbach M, Saliba 785 786 A-E, Sander LE. 2021. SARS-CoV-2 infection triggers profibrotic macrophage 787 responses and lung fibrosis. Cell 184:6243-6261.e27. 788 doi:10.1016/j.cell.2021.11.033
- Zhang Z, Luo D, Zhong X, Choi JH, Ma Y, Wang S, Mahrt E, Guo W, Stawiski EW,
  Modrusan Z, Seshagiri S, Kapur P, Hon GC, Brugarolas J, Wang T. 2019.
  SCINA: A Semi-Supervised Subtyping Algorithm of Single Cells and Bulk
  Samples. *Genes* 10:531. doi:10.3390/genes10070531

#### 794 FIGURES



796 Figure 1. Higher abundance of bronchoalveolar T cells in inflammatory post-COVID-797 19 lung disease (PCLD). a Representative computed tomography (CT) images for each radiological phenotype. **b** Uniform manifold approximation and projection 798 799 (UMAP) embedding of 55,776 bronchoalveolar single-cell transcriptomes obtained 800 from five individuals with radiological features of pulmonary inflammation (33,553 30

801 cells) and five individuals with radiological features of pulmonary fibrosis (22,223 cells) 802 following COVID-19, split by PCLD phenotype, color coded by cell type. Cell type 803 annotation was achieved by assignment of Azimuth human lung reference gene 804 signatures using the SCINA R package and in the case of dendritic cells and B cells, 805 expression of literature-based markers. Prolif = proliferating cells, identified by their 806 high module score for a gene signature representing the cellular proliferation 807 response. c Cellular composition of each BAL sample defined by single-cell RNA 808 sequencing (scRNAseq). Color indicates cell type and bar height represents 809 proportion. **d** Dot plot visualization of the expression of independently established 810 marker genes for each cell type; "Mac" = macrophage. Dot size represents the 811 percentage of cells expressing the gene in each cell type, color shows the z-scores of 812 average log-normalized expression for each cell type compared to the entire data set. 813 e Comparison of the proportions of each cell type in inflammatory and fibrotic PCLD. 814 Horizontal lines indicate median, box limits the interguartile range and whiskers the 5<sup>th</sup> 815 to  $95^{\text{th}}$  percentiles, \* = FDR<0.05.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287759; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license . Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID lung disease



Figure 2. Post-COVID-19 bronchoalveolar T cells are dominated by CD4 central 818 819 memory and CD8 effector memory subsets. a UMAP embedding of 9196 820 transcriptomes of T cells identified in Figure 1b, colored by cell type. T cell subset 821 annotation was based on assignment of Azimuth human PBMC reference marker 822 gene signatures and additional published CD4 T cell signatures by the SCINA R 823 package. b Relative proportions of each T cell subset in each subject, colors represent 824 cell type. **c** Feature plots demonstrating the expression of marker genes for the three 825 principal T cell subsets and NK cells, colored by scaled, log-normalized counts, 826 projected on to the T cell UMAP. **d** Comparison of the proportions of T cell subsets 827 found in all individuals in inflammatory and fibrotic post-COVID-19 lung disease 828 (PCLD). Horizontal lines indicate median, box limits the interguartile range and whiskers the 5<sup>th</sup> to 95<sup>th</sup> percentiles. 829

medRxiv preprint doi: https://doi.org/10.1101/2023.03.28.23287759; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license . Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID lung disease



832 Figure 3. Bronchoalveolar macrophage and monocyte subsets in post-COVID-19 lung 833 disease (PCLD). a UMAP embedding of 38,010 macrophage transcriptomes identified 834 in Figure 1b, colored by cell type. Myeloid populations were annotated by assignment 835 of Azimuth human lung reference marker genes and additional signatures derived from 836 published literature using the SCINA R package and by visualising expression of 837 canonical marker genes for some subsets. **b** Relative proportions of each myeloid subset within each individual, colors represent cell type. **c** Expression of marker genes 838 839 for PCLD macrophage and monocyte populations, colored by scaled, log-normalized

840 counts, projected on to the myeloid cell UMAP. d Dot plot visualization of the 841 expression of selected marker genes for each macrophage and monocyte subset. Dot 842 size represents the percentage of cells expressing the gene in each myeloid subset, 843 color shows the z-scores of average log-normalized expression for each subset 844 compared to the entire data set. e Expression of a profibrotic macrophage gene 845 signature derived from idiopathic pulmonary fibrosis, calculated on a single-cell level, 846 colored by module score and projected on to the macrophage UMAP. **f** Comparison 847 of the proportions of bronchoalveolar myeloid populations in inflammatory and fibrotic 848 PCLD. Horizontal lines indicate median, box limits the interguartile range and whiskers 849 the 5<sup>th</sup> to 95<sup>th</sup> percentiles.



Figure 4. Highly similar T cell receptors (TCRs) characterize both inflammatory and 852 35

853 fibrotic post-COVID lung disease (PCLD). **a** T cell clonal expansion is visualized on 854 the T cell UMAP split by radiological PCLD phenotype. TCR sequences detected at a 855 frequency of greater than one are colored light blue and contour lines provide a 2D 856 representation of TCR density overlaid in red for inflammatory PCLD and blue for 857 fibrotic PCLD. **b** Comparison of the proportion of expanded TCR sequences, defined 858 as those detected at a frequency greater than one in the three largest T cell subsets 859 identified in Figure 2a in the two PCLD phenotypes. c Percentage of complementarity 860 determining region (CDR)3 alpha and beta chain amino acid sequences clustering and 861 number of clusters generated over a range of thresholds above which two TCRs are 862 considered similar, for inflammatory and fibrotic PCLD bronchoalveolar lavage (BAL) 863 samples, negative control PBMC samples not expected to cluster highly and positive 864 control PBMC samples known to cluster highly, analyzed separately. **d** Representative network diagrams of TCR  $\beta$  chain clusters present in each group described in (c). 865 866 Nodes represent TCRs, related TCRs are connected by an edge and colors represent 867 the groups. **e** Network diagrams of related TCR  $\beta$  chains in each PCLD phenotype in 868 which nodes are colored by donor. **f** Network diagrams visualizing TCR  $\beta$  chain 869 clusters identified by combined analysis of the two PCLD phenotypes. Nodes are 870 colored by donor (right) or radiological phenotype and membership of clusters 871 composed of one or both PCLD groups (left), circular nodes represent inflammatory 872 PCLD and square nodes fibrotic PCLD. **g** Number of TCR sequences ( $\alpha$  and  $\beta$  genes 873 combined) annotated for SARS-CoV-2, cytomegalovirus (CMV), and Epstein-Barr 874 virus (EBV) in VDJdb either detected or not detected in TCR sequences from 875 individuals with each PCLD phenotype and negative controls, giving the odds ratio 876 ±95% confidence interval (Fisher's exact test) for enrichment of antigen-specific TCR

## 877 sequences in each instance.

#### TABLES 879

880 
**Table 1.** Clinical and demographic information summary.

	Inflammatory N=5	Fibrotic N=5		
Age				
Median (IQR)	62 (21.5)	59 (8.5)		
Sex				
Male	2 (40%)	4 (80%)		
Female	3 (60%)	1 (20%)		
Ethnicity				
White	3 (60%)	3 (60%)		
Asian	2 (40%)	2 (40%)		
Body mass index (kg/m²)				
Median (IQR)	31.8 (15.6)	27.3 (6.1)		
Smoking Status				
Never	4 (80%)	2 (40%)		
Former	1 (20%)	3 (60%)		
COVID-19 wave				
1	2 (40%)	2 (40%)		
2	3 (60%)	3 (60%)		
Respiratory Support				
I&V†	2* (40%)	4 (80%)		
CPAP‡	1 (20%)	0		
HFNO‡	1 (20%)	1 (20%)		
nil	1 (20%)	0		
Treatment for COVID-19				
Steroid	3 (60%)	5 (100%)		
Tocilizumab	1 (20%)	1 (20%)		
Anti-viral	0	0		
BAL				
Days post-acute COVID (median (IQR))	116 (50)	316 (50.5)		

881 \*One patient also received ECMO (extracorporeal membrane oxygenation); †I&V

Intubation and ventilation; ‡CPAP Continuous Positive Airways Pressure; ‡HFNO 882

883 High Flow Nasal Oxygen.

#### 884 Support statement

- PM is supported by a Medical Research Council (MRC)/GlaxoSmithKline
  Experimental Medicine Initiative to Explore New Therapies network (EMINENT)
  Clinical Research Training Fellowship. EKD is supported by Breathing Matters. MZN
  is supported by a UK MRC Clinician Scientist Fellowship (MR/W00111X/1) and a
  Rutherford Fund Fellowship allocated by the MRC UK Regenerative Medicine Platform
  2 (MR/5005579/1). MN is supported by the Wellcome Trust (207511/Z/17/Z). GST is
- supported by a UK MRC Clinician Scientist Fellowship (MR/N007727/1). PM, EKD,
- MP, JSB, MZN, MN, RCC, JCP and GST are also supported by NIHR Biomedical
- 893 Research Funding to UCL and UCLH.

## 894 Author contributions

- 895 GST, JCP, RCC and MZN conceived the study.
- EKD, PM, KBW, MY, JCP and GST collected the data.
- 897 PM, EKD, KW, MY 10x Genomics platform.
- 898 BSMDDE, CTT, KF, MM, MZN, MP, JSB, BMC and MN provided resources or analysis

899 tools.

- 900 BSMDDE, KF and GST performed the computational data analysis with contributions
- 901 from AM, MM, BMC and MN.
- 902 PM, BSMDDE, EKD and GST prepared the manuscript draft.
- 903 All authors reviewed and contributed to the final manuscript.
- 904 **COMPETING INTERESTS**
- 905 All authors declare no competing interests.

906